Related Experiment Video
Updated: May 15, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
The risk of AKI in patients treated with intravenous solutions containing hydroxyethyl starch
1Department of Anesthesiology, Duke University Medical Center, and Durham Veterans Affairs Medical Center, Durham, North Carolina 27705, USA. andrew.shaw@duke.edu
Abstract:
Intravenous fluids are arguably one of the most commonly administered inpatient therapies and for the most part have been viewed as part of the nephrologist's toolkit in the management of acute kidney disease. Recently, findings have suggested that intravenous fluids may be harmful if given in excess (quantitative toxicity) and that some may be more harmful than others (qualitative toxicity), particularly for patients who already have AKI. Recent clinical trials have investigated hydroxyethyl starch solutions and found worrying results for the renal community. In this brief review, we consider the published literature on the role of hydroxyethyl starch solutions in AKI, with particular emphasis on two large recent randomized clinical trials conducted in Europe and Australia.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury I: Introduction
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury III: Clinical Manifestations